^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)

    i
    Other names: HLA-DQB2, Major Histocompatibility Complex, Class II, DQ Beta 2, HLA-DXB, HLA Class II Histocompatibility Antigen, DQ Beta 2 Chain, HLA Class II Histocompatibility Antigen, DX Beta Chain, MHC Class II Antigen DQB2, DV19.1 (Major Histocompatibility Complex, Class II, DQ Beta 2 (HLA-DXB)), HLA-DQB1, DQB2
    Associations

    News

    Trials
    3ms
    Identification of a Treg-related gene signature for predicting prognosis and immunosuppression in skin cutaneous melanoma. (PubMed, Clin Exp Med)
    qRT-PCR and Western blot confirmed PTPRF, ULK1, TGM3, and CRABP2 were upregulated at both the mRNA and protein levels. These findings indicate that the Treg-related signature serves as robust prognostic biomarkers and may guide personalized immunotherapy in SCKM.
    Journal • Gene Signature • IO biomarker
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • PTPRF (Receptor-type tyrosine-protein phosphatase F) • CRIP1 (Cysteine Rich Protein 1) • KHDRBS3 (KH RNA Binding Domain Containing, Signal Transduction Associated 3) • MIR375 (MicroRNA 375) • TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    4ms
    Local Genetic Correlations and Pleiotropy Reveal Shared Genetic Architecture Between COVID-19 Phenotypes and Prostate Cancer in European Populations. (PubMed, J Cancer)
    These findings highlight common biological mechanisms rather than direct causal relationships, suggesting the limited benefits of additional PrCa screening in COVID-19 survivors. Furthermore, the identified genes represent promising targets for future mechanistic research and clinical interventions, warranting further validation.
    Journal
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • ADAM15 (ADAM Metallopeptidase Domain 15) • HLA-C (Major Histocompatibility Complex, Class I, C) • TCF19 (Transcription Factor 19) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    1year
    Gene expression levels associated with impaired immune response and increased proliferation could serve as biomarkers for women following cervical cancer screening programmes. (PubMed, Front Immunol)
    Statistically significantly higher median expression levels of CDKN2A (p < 0.001) and KRT7 (p = 0.045) and significantly lower expression of ARG1 (p = 0.012) were found in biopsies with HOP-HPV infections, with no difference detected for HLA-DQB2 (p = 0.82). Models using expression levels of CDKN2A (AUC, 0.91; 95% CI, 0.86-0.95), KRT7 (0.86, 0.81-0.91), or ARG1 (0.78, 0.70-0.85) together with HOP/LOP-HPV class were significantly better than HPV class alone (0.72, 0.66-0.79) in discriminating CIN2/3 versus CIN1 (p < 0.001, p < 0.001, and p = 0.014, respectively).
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • KRT7 (Keratin-7) • ARG1 (Arginase 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    1year
    Integration of osimertinib-targeted EGFR gene-associated differential gene expression in constructing a prognostic model for lung adenocarcinoma. (PubMed, Funct Integr Genomics)
    The constructed prognostic model showed promise in predicting the survival of LUAD patients. Notably, KCTD12 and CCT6A might be candidate biomarkers for improving diagnostic performance and guiding individualized therapy for EGFR-TKI-resistant LUAD patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CD73 (5'-Nucleotidase Ecto) • BIRC3 (Baculoviral IAP repeat containing 3) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • NT5E (5'-Nucleotidase Ecto) • CPLX2 (Complexin 2) • MUC15 (Mucin 15) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    |
    CD73 expression
    |
    Tagrisso (osimertinib)
    over1year
    Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC) (SABCS 2024)
    These data indicate that HR+/HER2- MaBC has a differential mutational spectrum and TMB-high frequency, MHC Class I and MHC class II, drug efflux and stem cell-related gene expression compared to their HR+/HER2- FeBC counterparts. These suggest important differences in tumor biology between men and women with HR+/HER2- breast cancer. A better understanding of these differences with additional research may help in design future clinical trials and treatments for men with HR+/HER2- BC.
    Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • CDH1 (Cadherin 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • KLF4 (Kruppel-like factor 4) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • HLA-B (Major Histocompatibility Complex, Class I, B) • GATA3 (GATA binding protein 3) • PROM1 (Prominin 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    |
    TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • HER-2 mutation • HER-2 expression • EGFR positive • AR expression
    |
    PD-L1 IHC 22C3 pharmDx
    over1year
    Integrating Bulk and Single-Cell RNA-Seq Data to Identify Prognostic Features Related to Activated Dendritic Cells in Clear-Cell Renal-Cell Carcinoma. (PubMed, Int J Mol Sci)
    Molecular docking indicated high-affinity binding of the proteins encoded by these genes with JQ1. In conclusion, our study reveals the crucial role of activated DCs in ccRCC, offering new insights into predicting immune response, targeted therapy effectiveness, and prognosis for ccRCC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • IFNG (Interferon, gamma) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    |
    IFNG expression
    |
    JQ-1
    over1year
    Tumor microenvironment-based signatures distinguish intratumoral heterogeneity, prognosis, and immunogenomic features of clear cell renal cell carcinoma. (PubMed, J Natl Cancer Cent)
    The TMErisk score can be utilized as an innovative independent prognosis predictive marker with high sensitivity and accuracy. Our discovery also predicted the efficacy of immunotherapy in ccRCC patients, indicating the intimate link between tumor immune microenvironment and intratumoral heterogeneity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SLFN11 (Schlafen Family Member 11) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    over1year
    A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report. (PubMed, Transl Lung Cancer Res)
    A 73-year-old female was initially started on carboplatin, pemetrexed and pembrolizumab with maintenance, but eventually had progression in the left upper lobe (LUL). The patient's response to a MET inhibitor, tepotinib, underscores the potential efficacy of selective MET inhibitors for individuals with previously unexplored MET fusions. The positive response to tepotinib of a patient with NSCLC harboring a novel MET-Fusion underscores the importance of the use of comprehensive next-generational sequencing-based panels and highlights the necessity for additional research and clinical exploration of selective MET inhibitors for managing NSCLC with MET rearrangements.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Tepmetko (tepotinib)
    almost2years
    Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer. (PubMed, Thorac Cancer)
    Our data suggested a pivotal role of TLSs formation in survival outcome and immunotherapy response of NSCLC patients. Tumors with mature TLS formation showed more activated immune microenvironment. In addition, the model constructed by TLS-related genes could predict the response to immunotherapy and is meaningful for clinical decision-making.
    Journal
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    2years
    Disulfidptosis-related prognostic signature correlates with immunotherapy response in colorectal cancer. (PubMed, Sci Rep)
    In conclusion, DSP-related genes actively participated in regulating the tumour microenvironment. Thus, they can serve as biomarkers to provide targeted treatment for colorectal cancer.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    2years
    The gene expression profile and cell of origin of canine peripheral T-cell lymphoma. (PubMed, BMC Cancer)
    Canine CD4+ PTCL most closely resembled the GATA3-PTCL subtype of PTCL-NOS and may originate from an earlier stage of T-cell development than the more conventionally posited mature T-helper cell origin.
    Journal • Gene Expression Profile • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • GATA3 (GATA binding protein 3) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    |
    CD8 expression